Expanding access to medicines for people living in the world's poorest countries

GlaxoSmithKline (GSK)As part of its commitment to further transform the company's approach to diseases that disproportionately affect the world's poorest people, GlaxoSmithKline (GSK) is creating a new operating unit dedicated to the Least Developed Countries (LDCs*). A new Developing Countries and Market Access operating unit has been created which will integrate GSK's pharmaceutical business in LDCs into one group. The group will provide a dedicated focus on the strategic approaches needed to expand access to medicines for patients living in these countries.

Andrew Witty, Chief Executive Officer, GSK, said, "Access to medicines continues to become hardwired into the way we do our business as we seek new solutions to challenges in all the communities in which we operate. Creating an operating unit specifically for the Least Developed Countries builds on our commitment to change the landscape of healthcare for the world’s poorest people."

Duncan Learmouth is appointed to lead this new group, effective 1 August. He will report to Abbas Hussain, President, Emerging Markets/Asia Pacific. The new group will also include the Market Access function that supports access programmes and policies for the wider Emerging Markets and Asia Pacific (EMAP) Region.

* As defined by the UN there are currently 49 Least Developed Countries (LDCs) of which 33 are in Africa. Structural weaknesses, poverty, susceptibility to natural and man-made disasters and to communicable diseases hamper the efforts of these countries to improve the quality of life of their people.

GSK recently reduced the prices of its patented medicines by an average of 45% in LDCs. The company is also reinvesting 20% of profits from medicines in LDC countries back into projects that strengthen healthcare infrastructure and help widen access to medicines.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...